$ONCS gap breakout Nasdaq $2.95 5-bagger correct
Post# of 121
Posted On: 03/23/2016 7:57:11 AM
$ONCS gap breakout
Nasdaq $2.95
5-bagger corrected
Website
ultra low float
Shares Outstanding: 16.97M
Float: 14.67M
% Held by Insiders: 14.78%
% Held by Institutions: 6.20%
Shares Short (as of Feb 29, 2016): 154.87K
Short Ratio (as of Feb 29, 2016): 2.34
Short % of Float (as of Feb 29, 2016): 1.31%
Shares Short (prior month) 160.61K
Headlines
OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, and therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead program, ImmunoPulse IL-12, is in Phase II development for various indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companys therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company has also completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in Merkel cell carcinoma. It is also conducting four additional clinical trials of ImmunoPulse with DNA-encoded IL-12 comprising OMS-I100 Addendum and CC-15852 in metastatic melanoma, OMS-I130 in head and neck cancer, and OMS-I140 in triple-negative breast cancer. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of combination therapy with KEYTRUDA (pembrolizumab), Merck & Co.s anti-PD-1 therapy, and ImmunoPulse IL-12 in metastatic melanoma. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
Nasdaq $2.95
5-bagger corrected
Website
ultra low float
Shares Outstanding: 16.97M
Float: 14.67M
% Held by Insiders: 14.78%
% Held by Institutions: 6.20%
Shares Short (as of Feb 29, 2016): 154.87K
Short Ratio (as of Feb 29, 2016): 2.34
Short % of Float (as of Feb 29, 2016): 1.31%
Shares Short (prior month) 160.61K
Headlines
OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, and therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead program, ImmunoPulse IL-12, is in Phase II development for various indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companys therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company has also completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in Merkel cell carcinoma. It is also conducting four additional clinical trials of ImmunoPulse with DNA-encoded IL-12 comprising OMS-I100 Addendum and CC-15852 in metastatic melanoma, OMS-I130 in head and neck cancer, and OMS-I140 in triple-negative breast cancer. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of combination therapy with KEYTRUDA (pembrolizumab), Merck & Co.s anti-PD-1 therapy, and ImmunoPulse IL-12 in metastatic melanoma. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
(0)
(0)OncoSec Medical Incorporated (ONCS) Stock Research Links
Scroll down for more posts ▼